These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1078 related articles for article (PubMed ID: 31433303)

  • 21. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan.
    Liu CH; Peng CY; Liu CJ; Chen CY; Lo CC; Tseng KC; Su PY; Kao WY; Tsai MC; Tung HD; Cheng HT; Lee FJ; Huang CS; Huang KJ; Shih YL; Yang SS; Wu JH; Lai HC; Fang YJ; Chen PY; Hwang JJ; Tseng CW; Su WW; Chang CC; Lee PL; Chen JJ; Chang CY; Hsieh TY; Chang CH; Huang YJ; Kao JH
    Hepatol Int; 2023 Apr; 17(2):291-302. PubMed ID: 36701081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
    Da BL; Lourdusamy V; Kushner T; Dieterich D; Saberi B
    Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):859-861. PubMed ID: 32541241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
    Wong YJ; Thurairajah PH; Kumar R; Tan J; Fock KM; Law NM; Li W; Kwek A; Tan YB; Koh J; Lee ZC; Kumar LS; Teo EK; Ang TL
    J Gastroenterol Hepatol; 2021 May; 36(5):1300-1308. PubMed ID: 33217040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
    Bourlière M; Gordon SC; Flamm SL; Cooper CL; Ramji A; Tong M; Ravendhran N; Vierling JM; Tran TT; Pianko S; Bansal MB; de Lédinghen V; Hyland RH; Stamm LM; Dvory-Sobol H; Svarovskaia E; Zhang J; Huang KC; Subramanian GM; Brainard DM; McHutchison JG; Verna EC; Buggisch P; Landis CS; Younes ZH; Curry MP; Strasser SI; Schiff ER; Reddy KR; Manns MP; Kowdley KV; Zeuzem S;
    N Engl J Med; 2017 Jun; 376(22):2134-2146. PubMed ID: 28564569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
    von Felden J; Vermehren J; Ingiliz P; Mauss S; Lutz T; Simon KG; Busch HW; Baumgarten A; Schewe K; Hueppe D; Boesecke C; Rockstroh JK; Daeumer M; Luebke N; Timm J; Schulze Zur Wiesch J; Sarrazin C; Christensen S
    Aliment Pharmacol Ther; 2018 May; 47(9):1288-1295. PubMed ID: 29536554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.
    Gheorghe L; Preda C; Trifan A; Manuc M; Stanciu C; Istratescu D; Popescu CP; Diculescu MM; Tieranu CG; Manuc T; Stroie TG; Iacob SM; Iliescu L
    J Gastrointestin Liver Dis; 2022 Dec; 31(4):437-443. PubMed ID: 36535062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
    Lawitz E; Poordad F; Wells J; Hyland RH; Yang Y; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Landaverde C; Gutierrez J
    Hepatology; 2017 Jun; 65(6):1803-1809. PubMed ID: 28220512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
    Borgia SM; Dearden J; Yoshida EM; Shafran SD; Brown A; Ben-Ari Z; Cramp ME; Cooper C; Foxton M; Rodriguez CF; Esteban R; Hyland R; Lu S; Kirby BJ; Meng A; Markova S; Dvory-Sobol H; Osinusi AO; Bruck R; Ampuero J; Ryder SD; Agarwal K; Fox R; Shaw D; Haider S; Willems B; Lurie Y; Calleja JL; Gane EJ
    J Hepatol; 2019 Oct; 71(4):660-665. PubMed ID: 31195062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
    Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
    Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment failure with DAA therapy: Importance of resistance.
    Sarrazin C
    J Hepatol; 2021 Jun; 74(6):1472-1482. PubMed ID: 33716089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
    Garcia-Cehic D; Rando A; Rodriguez-Frias F; Gregori J; Costa JG; Carrión JA; Macenlle R; Pamplona J; Castro-Iglesias A; Cañizares A; Tabernero D; Campos C; Buti M; Esteban JI; Quer J
    J Viral Hepat; 2021 Sep; 28(9):1319-1324. PubMed ID: 33720484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].
    Li JP; Chen XF; Yan Q; Zhang YJ; Xie ZW; Xia Y; Guan YJ
    Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):831-837. PubMed ID: 33105927
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
    Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C
    Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.
    D'Ambrosio R; Pasulo L; Puoti M; Vinci M; Schiavini M; Lazzaroni S; Soria A; Gatti F; Menzaghi B; Aghemo A; Capelli F; Rumi MG; Morini L; Giorgini A; Pigozzi MG; Rossini A; Maggiolo F; Pan A; Memoli M; Spinelli O; Del Poggio P; Saladino V; Spinetti A; De Bona A; Capretti A; Uberti-Foppa C; Bonfanti P; Terreni N; Menozzi F; Colombo AE; Giglio O; Centenaro R; Borghi M; Baiguera C; Picciotto V; Landonio S; Gori A; Magnani C; Noventa F; Paolucci S; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Mar; 70(3):379-387. PubMed ID: 30472321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
    Gupta N; Manirambona L; Shumbusho F; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Mukabatsinda C; Musabeyezu E; Camus G; Grant PM; Kateera F
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):542-551. PubMed ID: 35248212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
    Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
    J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
    Gane EJ; Schwabe C; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CA
    Gastroenterology; 2016 Sep; 151(3):448-456.e1. PubMed ID: 27240903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.